SABCS to Showcase Advances in Breast Cancer Treatments

Editor’s note: When the San Antonio Breast Cancer Symposium (SABCS) kicks off next week, researchers will present the results of dozens of clinical trials. Among several eagerly anticipated studies is a phase II trial of the TKI inhibitor tucatinib, given in combination with trastuzumab (Herceptin) and capecitabine.

A version of this article on the tucatinib trial is freely available on the Cancer Discovery website, where you can find further coverage of SABCS throughout the meeting.

Read More

Cancer Survivors Become Advocates on Capitol Hill

As 2019 draws to a close, the American Association for Cancer Research (AACR) is grateful for our growing ranks of cancer patients and survivors who join us in advocating for strong federal funding for medical research. This year, Tomma Hargraves and Nicole Robinson joined us on Capitol Hill for the Rally for Medical Research, an annual gathering in which more than 300 national organizations ask lawmakers to make continued funding for the National Institutes of Health a priority.

Read More

Can Distress Screening Help Caregivers?

November is National Family Caregivers Month—a time to raise awareness for the approximately 3 million people in the U.S. who act as caregivers to their relatives, friends, or partners—all while juggling other demanding roles in life.

An article appearing in the fall issue of Cancer Today, a resource for cancer patients, survivors, and caregivers, highlights efforts to understand the nature of distress in caregiving and better ways to provide support for those who need it.

Read More

New AACR-Novocure Funding Initiatives Support Tumor Treating Fields Research

Earlier this year, the American Association of Cancer Research (AACR) partnered with Novocure, a global oncology company, to launch several new funding initiatives to support innovative research focused on Tumor Treating Fields (TTFields). TTFields is a novel noninvasive cancer therapy approved by the U.S. Food and Drug Administration for the treatment of adults with glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Patients wear a portable electric field generator that delivers TTFields to tumors via electrodes attached to the skin over the tumor site.

Read More

Targets Conference Showcases Exciting Data from Clinical Trials of Innovative Cancer Therapeutics

There has been an explosion in the number of cancer therapeutics and clinical trials in the recent past, owing to our ability to better define the molecular targets of different cancers using cutting-edge technologies. Unlike in the past, data from early-stage clinical trials are getting more attention lately because the efficacy of a therapeutic, traditionally evaluated in later-phase trials, is often becoming evident earlier in the course of clinical testing.

Read More

Molecular Targets and Cancer Therapeutics Conference Moves Targeting KRAS to the Fore

After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes altered in about a third of cancers, encouraging data emerging from clinical trials and preclinical studies suggest KRAS could finally be dethroned from the “undruggable” category.

Read More

Ovarian Cancer: Examining the Microenvironment and Mutational Landscapes to Tailor Treatments

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held this year at the Hynes Convention Center in Boston Oct. 26-30, has once again brought together members of academia, pharmaceutical industry, federal regulatory agencies, and all other stakeholders in the cancer drug development space from across the globe to discuss the most up-to-date advances.

A couple of studies presented at the conference set out to address an important question in cancer research – why is ovarian cancer so hard to treat?

Read More

FDA Approves Ovarian Cancer Treatment Based on New Biomarker

On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula) to include an additional group of patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: those whose cancer has progressed despite treatment with at least three different cytotoxic chemotherapy regimens and tests positive for a new biomarker called homologous recombination deficiency (HRD).

Read More

ESPN Reporter Holly Rowe Works Through Cancer

Sports are often referred to as a metaphor for life. But, for ESPN reporter Holly Rowe, sports are quite literally a way of life. When Rowe was undergoing treatment for desmoplastic melanoma, her passion for sports—and telling athletes’ stories from the sidelines—helped her muscle through her own personal struggles.

Read More